Clinical Trials Using Selective Androgen Receptor Modulator LY2452473

Clinical trials are research studies that involve people. The clinical trials on this list are studying Selective Androgen Receptor Modulator LY2452473. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • LY2452473 in Improving Symptom Management in Patients with Undetectable PSA after Surgery for Prostate Cancer

    This randomized phase II trial studies the side effects of selective androgen receptor modulator LY2452473 (LY2452473) and how well it works in improving symptom management in patients who have undergone surgery for prostate cancer and have had undetectable prostate-specific antigen (PSA) for 2 or more years after surgery. Reducing the hormone androgen is a way to treat prostate cancer. However, this may cause side effects such as difficulty with sexual function, muscles, and bones, and fatigue. LY2452473 may help reduce the symptoms of androgen deficiency in men with prostate cancer.
    Location: See Clinical Trials.gov